SEP 4·SEC EDGARLow
Fordyce Marshall sold $650K of VERA
Fordyce Marshall (PRESIDENT AND CEO) sold 18,500 shares of Vera Therapeutics, Inc. (VERA) at $35.12 ($0.65M total) on 2026-09-02 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$VERA
Vera Therapeutics, Inc.
Price · $VERAvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $650K 1 txs
Fordyce Marshall1× · $650K
10b5-1 share of filings100%
Top stories · $VERAMore →
AUG 30·stocktwits.com
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics
Vera Therapeutics (VERA) stock rose 7% after FDA approval of Trutakna for treating IgA Nephropathy. The drug showed a 46% reduction in proteinuria in trials. CEO Marshall Fordyce highlighted its potential to address unmet medical needs. VERA is up 90% over 12 months despite a 14% year-to-date decline.
AUG 10·SEC EDGAR 8-K
Vera Therapeutics, Inc. (VERA): Results of Operations and Financial Condition
Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results • TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. • A
VERA sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning VERA (Vera Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VERA coverage spans regulation, insider activity and corporate actions.
In the last 30 days, VERA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($650K). The most active reporter was Fordyce Marshall, PRESIDENT AND CEO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving VERA
Insider sale may signal reduced confidence, modest negative pressure on stock.
Regulatory approval unlocks commercial launch and revenue potential.
Near-term catalyst is the planned ORIGIN 3 final efficacy analysis in Q3 2026 and potential full-approval path, alongside cash burn and launch execution signals.
This is a routine equity-inducement grant with a defined strike price and vesting schedule, with limited direct impact on near-term fundamentals.
This is an insider sale disclosure, not a fundamental update, but it can modestly affect near-term sentiment.
alphai scores every news story that mentions VERA with an AI model for sentiment and relevance, and aggregates insider trades from Vera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $VERA
Score
Fordyce Marshall sold $650K of VERA
Fordyce Marshall (PRESIDENT AND CEO) sold 18,500 shares of Vera Therapeutics, Inc. (VERA) at $35.12 ($0.65M total) on 2026-09-02 under a Rule 10b5-1 trading plan.
1 min readVERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics
Vera Therapeutics (VERA) stock rose 7% after FDA approval of Trutakna for treating IgA Nephropathy. The drug showed a 46% reduction in proteinuria in trials. CEO Marshall Fordyce highlighted its potential to address unmet medical needs. VERA is up 90% over 12 months despite a 14% year-to-date decline.
2 min readVera Therapeutics, Inc. (VERA): Results of Operations and Financial Condition
Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results • TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. • A
6 min read
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) said its Compensation Committee granted inducement awards on July 6, 2026 to eight new employees under its 2024 Inducement Plan. Awards include non-qualified stock options for 32,100 shares and RSUs for 16,050 shares. Options exercise at $40.13, the July 6 closing price, and both options and RSUs vest over four years.
2 min readFordyce Marshall sold $2.0M of VERA
Fordyce Marshall (PRESIDENT AND CEO) sold 46,250 shares of Vera Therapeutics, Inc. (VERA) at an average of $42.30 ($40.78–$43.59, $1.96M total) across 4 trades on 2026-07-07 under a Rule 10b5-1 trading plan.
1 min read
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics (Nasdaq: VERA) said Chief Regulatory Officer William Turner plans to retire in the third quarter and become Strategic Advisor. Nancy Boman, M.D., Ph.D., will succeed him as Chief Regulatory Officer. The company links Turner’s tenure to the accelerated approval of TRUTAKNA (atacicept-vymj) for IgA nephropathy proteinuria.
3 min readVera Therapeutics, Inc. (VERA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001831828 0001831828 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 09,
2 min read
Why Is Vera Therapeutics Stock Gaining Tuesday? - Vera Therapeutics (NASDAQ:VERA)
Vera Therapeutics (NASDAQ:VERA) shares rose about 9% after the FDA approved Trutakna under the accelerated approval pathway for IgA nephropathy. Interim Phase 3 ORIGIN 3 data for 203 participants showed statistically significant proteinuria reductions vs placebo (42% at 36 weeks; 46% UPCR reduction from baseline). Confirmatory benefit depends on ongoing ORIGIN 3 results expected in Q3 2026.
5 min read
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Vera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. In ORIGIN 3 interim analysis, TRUTAKNA cut UPCR 46% vs baseline and 42% vs placebo (statistically significant). Safety in 428 patients included infections (32% vs 28%) and injection reactions (30% vs 5%); long-term kidney benefit pending Q3 2026.
4 min read
What's Going on with Vera Therapeutics Stock on Monday? - Vera Therapeutics (NASDAQ:VERA)
Vera Therapeutics’ (NASDAQ:VERA) shares rose about 1% to $41.60 Monday after gaining ~30% over the past month. The company is awaiting an FDA decision due July 7 on accelerated approval of atacicept for IgA nephropathy, supported by ORIGIN 3 interim data showing proteinuria reductions vs placebo. eGFR results are expected in Q3 2026.
3 min read